Search results for: Market Access
Filter search results
Opportunities for Utilising ‘Real World Data’ in South Korea
20 October 2017
…Health Insurance Review and Assessment Service (HIRA). Processes for data access and use are clear and maintain strong requirements for data protection. However, access tends to be limited to state,…
Price Competition and Biosimilars
23 June 2010
…that push the biosimilars market in the other direction. These include, for example, sources of supply with lower variable costs, profit incentives for entry, participation of major pharma companies and…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
…cases. For policy makers, the demographics of ageing make innovation in financing essential. 4. Innovation and markets will be truly global as demand evolves in emerging markets and as new…
Bengt Jönsson Honoured for Contribution to Health Economics
6 August 2014
…The chapter contributed by OHE’s Adrian Towse[2] discusses Bengt’s observations in a 2011 publication[3] about the role of relative effectiveness research (RE) in the European medicines market. To ensure value…
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
…are generic, Hill et al. discuss the use of cost estimates and the removal of patent protection in the context of on-patent drugs. However, in many markets some recovery of…
The Value of International Volunteers’ Experience to the NHS
24 April 2019
…market programmes: Investment climate and infrastructure, Labour market regulations and institutions, and Education and skills development. The monetary value of these outcomes is quantified through productivity indices which capture the…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…parallel, global antibiotic development pipelines are weak, due to the scientific, regulatory, and economic challenges of bringing new antibiotics to the market. Various R&D incentives (‘push’ and ‘pull’) have been…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
…approved by the FDA. They project that 8 therapies would fail to reach the market during the first decade as a result of H.R. 3, and a further 30 therapies…
Biosimilars: How Much Entry and Price Competition Will Result?
1 December 2010
This publication reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market for biosimilars and the implications of these for potential savings. Economists and…